Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 12, 2021

SELL
$13.03 - $17.09 $2.61 Million - $3.42 Million
-200,000 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$12.67 - $23.19 $2.53 Million - $4.64 Million
200,000 New
200,000 $2.81 Million

Others Institutions Holding BCEL

About Atreca, Inc.


  • Ticker BCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,876,000
  • Description
  • Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...
More about BCEL
Track This Portfolio

Track Maven Securities LTD Portfolio

Follow Maven Securities LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maven Securities LTD with notifications on news.